Log In
BCIQ
Print this Print this
 

Tapcom, tafluprost/timolol maleate (Taptiqom) (DE-111)

  Manage Alerts
Collapse Summary General Information
Company Santen Pharmaceutical Co. Ltd.
DescriptionFixed dose combination of Prostaglandin F2 alpha derivative and a beta-adrenergic receptor blocker
Molecular Target Prostaglandin F2 alpha receptor (PGF2 alpha) ; Adrenergic receptor beta (ADRB)
Mechanism of ActionAdrenergic receptor beta (ADRB) antagonist
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$700.0M

$600.0M

$100.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/13/2014

$700.0M

$600.0M

$100.0M

Get a free BioCentury trial today